Akebia Therapeutics (AKBA) Reports In-Line Q3 EPS

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $40.12 million versus the consensus estimate of $49.18 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SanDisk upgraded at JPMorgan after investor day; shares climb